Hybridoma technology has forged remarkable new approaches toward therapeutic mAb discovery, as well as disease diagnosis and prevention. Synbio Technologies has a robust antibody drug discovery platform utilized by our talented scientific team from both local and international antibody specialists. This platform provides a full range of services in custom monoclonal antibody production including immunization, hybridoma development, antibody discovery, antibody functional screening assays, antibody engineering, and antibody expression. Using this platform, we can deliver up to 10 high-quality functional hybridoma clones to jumpstart our customers’ antibody research.

• Proprietary Immunization Technology: Compared to traditional immunogen design, our Universal Antigen^TMcan induce antibodies to recognize epitopes containing less than 5 amino acids.
• One Stop Solution: Streamlined strategy from immunization to hybridoma generation and characterization.
• Reliable High-Throughput Screening Assays: Optimized immunization and high-throughput screening for affinity measurements, epitope binning, isotyping, etc.
• Comprehensive Functional Assay: Extensive experience in antibody affinity ranking, affinity measurement, cross-reactivity, and other in-vitro biological analysis.